Literature DB >> 23170795

A key role for connexin hemichannels in spreading ischemic brain injury.

Joanne O Davidson1, Colin R Green, Laura Bennet, Louise F B Nicholson, Helen Danesh-Meyer, Simon J O'Carroll, Alistair J Gunn.   

Abstract

Brain damage resulting from cerebral ischemia remains a significant problem at all stages of life. In adults, ischemic stroke is the third leading cause of death and the leading cause of disability in the developed world. In term newborns, moderate to severe brain damage after hypoxia-ischemia (HI) occurs in 1-3 per 1000 live births. One of the most striking features of HI injury is that after initial recovery of cellular oxidative metabolism, there is a delayed, 'secondary' mitochondrial failure that spreads over time from the most severely damaged areas outwards, into previously undamaged regions. This secondary failure is accompanied by transient seizure activity and cytotoxic edema. The specific mechanisms of this spread are poorly understood, but it is at least partly associated with spreading waves of depression that can trigger cell death in neighboring uninjured tissues. The waves are propagated through cell-cell communication via gap junction channels (the so called "bystander effect"). It has recently been proposed that unopposed connexin hemichannels (connexons) also play a significant role by mediating release of paracrine molecules that in turn propagate cell death messages by releasing intracellular mediators such as ATP, NAD(+), or glutamate or by abnormally prolonged opening to allow cell edema. There is increasing evidence that connexin hemichannels contribute to injury after many neural insults and that it is possible to significantly reduce the spread of damage after injury by suppressing the induction or activity of the connexin proteins that form hemichannels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23170795     DOI: 10.2174/138945013804806479

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  27 in total

1.  Astroglial connexin43 contributes to neuronal suffering in a mouse model of Alzheimer's disease.

Authors:  C Yi; X Mei; P Ezan; S Mato; I Matias; C Giaume; A Koulakoff
Journal:  Cell Death Differ       Date:  2016-07-08       Impact factor: 15.828

2.  Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease.

Authors:  Odunayo O Mugisho; Colin R Green; David M Squirrell; Sarah Bould; Helen V Danesh-Meyer; Jie Zhang; Monica L Acosta; Ilva D Rupenthal
Journal:  J Mol Med (Berl)       Date:  2018-12-08       Impact factor: 4.599

Review 3.  Gap junction channels as potential targets for the treatment of major depressive disorder.

Authors:  Qian Ren; Zhen-Zhen Wang; Shi-Feng Chu; Cong-Yuan Xia; Nai-Hong Chen
Journal:  Psychopharmacology (Berl)       Date:  2017-11-25       Impact factor: 4.530

Review 4.  Can heart function lost to disease be regenerated by therapeutic targeting of cardiac scar tissue?

Authors:  Emily L Ongstad; Robert G Gourdie
Journal:  Semin Cell Dev Biol       Date:  2016-05-24       Impact factor: 7.727

5.  Chronic Cerebral Hypoperfusion Induced Synaptic Proteome Changes in the rat Cerebral Cortex.

Authors:  Katalin Völgyi; Péter Gulyássy; Mihail Ivilinov Todorov; Gina Puska; Kata Badics; Dávid Hlatky; Katalin Adrienna Kékesi; Gabriella Nyitrai; András Czurkó; László Drahos; Arpád Dobolyi
Journal:  Mol Neurobiol       Date:  2017-06-15       Impact factor: 5.590

6.  Extracellular vesicle-mediated long-range communication in stressed retinal pigment epithelial cell monolayers.

Authors:  Navjot Shah; Masakii Ishii; Carlene Brandon; Zsolt Ablonczy; Jingwen Cai; Yutao Liu; C James Chou; Bärbel Rohrer
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-21       Impact factor: 5.187

7.  Maternal treatment with glucocorticoids modulates gap junction protein expression in the ovine fetal brain.

Authors:  G B Sadowska; B S Stonestreet
Journal:  Neuroscience       Date:  2014-06-11       Impact factor: 3.590

Review 8.  Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.

Authors:  Rainer Schulz; Philipp Maximilian Görge; Anikó Görbe; Péter Ferdinandy; Paul D Lampe; Luc Leybaert
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

9.  Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats.

Authors:  Yilin Mao; Tara Nguyen; Ryan S Tonkin; Justin G Lees; Caitlyn Warren; Simon J O'Carroll; Louise F B Nicholson; Colin R Green; Gila Moalem-Taylor; Catherine A Gorrie
Journal:  Exp Brain Res       Date:  2017-07-19       Impact factor: 1.972

10.  Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia.

Authors:  Ying-Shan Chen; Colin R Green; Rebecca Teague; Joshua Perrett; Helen V Danesh-Meyer; Istvan Toth; Ilva D Rupenthal
Journal:  Drug Deliv Transl Res       Date:  2015-10       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.